Skip to main content

Table 4 The Dose A and B vaccine recipients who responded to DPX-0907 vaccination and their immune response to vaccine antigens

From: First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

Patient

ID

Cancer Type

Vaccine Dosage

MHC Pentamer

ICS – Flow cytometry

 
   

Antigen Positive

Study day Positive

Positive Stimulus

Study day Positive

Multi-cytokine Positive

04-06a

Breast

0.25 mL

P5 P15

21, 42 42

P5 Pool

42 42

Yes Yes

01-13b

Breast

0.25 mL

None

NA

Pool

21

Yes

05-14b

Ovarian

0.25 mL

P4

21, 42

Pool

21, 42c

Yes, Noc

05-15b

Ovarian

0.25 mL

P3 P7 P13

73 73 73

None

NA

No

03-17b

Prostate

0.25 mL

None

NA

Pool

21c, 73

Noc, Yes

04-19b

Breast

1.0 mL

None

NA

Pool

42, 73

Yes, Yes

05-07

Ovarian

1.0 mL

P15

73

Pool

21

Yes

02-09

Ovarian

1.0 mL

P5 P3

42, 73 42

None

NA

No

01-22b

Ovarian

1.0 mL

P5

21, 73

Pool

21, 42c, 73c

Yes, Noc Noc

04-10a

Prostate

1.0 mL

P5 P7 P15

21, 42 42 21, 42

P13, P15, Pool

42 42c 42

Yes Noc Yes

01-18b

Prostate

1.0 mL

P4 P7

42 21, 42, 73

Pool

21c, 42c, 73c

Noc, Noc, Noc

  1. aMHC-multimer positive CD8 T cells were also detected ex vivo in these patients: Subject 04-06, P5 (0.12% staining frequency) on SD42; Subject 04-10, P5 on SD21 (0.11%) and on SD42 (0.23%).
  2. bPBMC from these patients were tested against pooled peptides only in ICS assay.
  3. cT cells from PBMC at the indicated study day produced detectable levels of one of the cytokines tested (IFN-γ, TNF-α, IL-2).